Currently, private pharmaceutical drug development is seen through the patent lens because there is no other way create a scalable business model. What is needed is to convince payers (e.g. health insurers, govt, or philanthropy) to back pay for success contracts and agree to purchase valuable off-patent RCT data rather than just RCT data involving a new patented drug which is capable of being monopolised. Without that, there is no market and no way to leverage this arbitrage opportunity.
This would allow tools such as Medikanren and other AI and personalised medicine approaches to drug discovery to be properly utilised. Doctors need RCTs to know which drugs are safe and effective and unfortunately, those RCTs are expensive, which creates a market failure if there is no ROI possible with patents. You can't solve a market failure with direct public funding, it's too inefficient. You need to update the social contracts to create a new market.
You are correct, it's the same "public goods" problem for FOSS projects, but for medicines, and uses a "bounty" model to solve it, but has not been implemented to date.
This would allow tools such as Medikanren and other AI and personalised medicine approaches to drug discovery to be properly utilised. Doctors need RCTs to know which drugs are safe and effective and unfortunately, those RCTs are expensive, which creates a market failure if there is no ROI possible with patents. You can't solve a market failure with direct public funding, it's too inefficient. You need to update the social contracts to create a new market.
You are correct, it's the same "public goods" problem for FOSS projects, but for medicines, and uses a "bounty" model to solve it, but has not been implemented to date.